Harmful enzyme may be key in rheumatoid arthritis

LONDON (Reuters) - Joint damage suffered by people with rheumatoid arthritis may be caused by antibodies produced within the joint itself, British researchers said Tuesday in a study that may help development of new drugs.

The study of joint biopsies from people with the condition which was then transplanted into mice found that tiny structures in the joint lining can lead to production of a destructive enzyme called activation-induced cytidine deaminase (AID).

This gives researchers a target to design new drugs for rheumatoid arthritis, a painful condition affecting an estimated 20 million people worldwide, Constantino Pitzalis of Barts and the London School of Medicine and colleagues wrote.

New treatments are critical because immune-suppressing drugs for the condition can produce serious side effects including stomach bleeding, ulcers, heart attacks and stroke while also raising the risk of death from infections and cancer.

“We therefore propose that AID may be targeted for the development of novel therapeutic agents,” the researchers wrote in the Public Library of Science Journal PLoS Medicine.

Rheumatoid arthritis is an autoimmune disease caused when the body confuses healthy tissues for foreign substances and attacks itself.

Some drugs to treat the condition seek to reduce inflammation directly while others tone down the immune system’s response, which can leave some patients vulnerable to infections and cancer.

The British team collected tissue from the lining of the joints of 55 people with rheumatoid arthritis and transplanted it under the skin of mice without immune systems.

Four weeks later, the researchers found that the transplanted tissue was still making the potentially destructive antibody, suggesting such production within joints can occur independently of the body’s lymph nodes.

The study is available at: “>here

(Reporting by Michael Kahn; Editing by Maggie Fox and Giles Elgood)


Related Posts:

HONG KONG (Reuters) - Researchers in Australia have designed a drug which appears effective in treating arthritis in mice, and they hope it can be used to treat diseases like rheumatoid arthritis and lupus in people. In an article published in Immunology and Cell Biology, the scientists said they zeroed in on a certain human receptor,

Full Post: New inhibitor drug seen for arthritis, lupus

NEW YORK (Reuters Health) - The immune-modulating drug leflunomide is effective as co-therapy with drugs that block the inflammation-producing protein TNF in people with rheumatoid arthritis, according to a report published this month. Rheumatoid arthritis, or RA, occurs when the immune system attacks the tissues that line the joints, leading to pain, inflammation and deformity. Rheumatoid

Full Post: Leflunomide effective as co-therapy in RA

Hemarthrosis is characterized with bleeding associated to a joint cavity. A joint that exhibits hemarthrosis in frequent episodes, it is named a target joint. It means that the same joint needs to experience at least 4 bleeds separately in a span of 6 months. The joints that are mostly affected include ankles, elbows, and knees,

Full Post: Everything about Hemarthrosis

NEW YORK (Reuters Health) - The health status of people with rheumatoid arthritis improved between 1994 and 2004, according to a new study. The researchers suggest this is most likely the result of better and more aggressive treatments. “Over the last decade, major changes have occurred in the provision of health care for patients with rheumatoid

Full Post: Rheumatoid arthritis therapy has improved steadily

NEW YORK (Reuters Health) - In children with arthritis, the time from diagnosis to the start of treatment with methotrexate appears to be an important predictor of their response to the drug at 6 months, Dutch investigators report. “Our results suggest that earlier initiation of methotrexate treatment will lead to an increased response,” Dr. R. ten

Full Post: Kids with arthritis benefit from early treatment

Site Navigation

Most Read



  • kinwrite.com@gmail.com